Programs

Presentations and Publications

Recent Presentations and Publications | Voxelotor Safety and Efficacy | Voxelotor Mechanism of Action | Selected Key Sickle Cell Disease ResearchSelected Key Transcranial Doppler ResearchAdditional Sickle Cell Disease Research



Recent Presentations and Publications

24th European Hematology Association (EHA) Congress (2019)

Presidential Symposium / Oral Presentation
Results From the Randomized, Placebo-Controlled, Phase 3 Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial of Voxelotor in Adults and Adolescents With Sickle Cell Disease

Poster Presentation
Cerebral Blood Flow in Adolescents with Sickle Cell Anemia Receiving Voxelotor

Poster Presentation
Central Physiologic Mechanisms Which Augment O2 Release (Bohr Effect and 2,3-DPG Binding) Are Preserved in the Presence of Voxelotor at the Therapeutic Target of 30% Hb Modification



Pharmacokinetics and Pharmacodynamics of Voxelotor (GBT440) in Healthy Adults and Patients With Sickle Cell Disease
British Journal of Clinical Pharmacology, Hutchaleelaha et al, February 2019

A Phase 1/2 Ascending Dose Study and Open-Label Extension Study of Voxelotor in Patients with Sickle Cell Disease
Blood, Howard et al, January 2019

Low Hemoglobin Increases Risk for Stroke, Kidney Disease, Elevated Pulmonary Artery Systolic Pressure, and Premature Death in Sickle Cell Disease: A Systematic Literature Review and Meta-Analysis
60th American Society of Hematology Annual Meeting & Exposition, Ataga et al, December 2018

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease
60th American Society of Hematology Annual Meeting & Exposition, Vichinsky et al, December 2018

Interim Results From a Phase 2a Study (GBT440-007) Evaluating Adolescents With Sickle Cell Disease Treated with Multiple Doses of Voxelotor (GBT440)
60th American Society of Hematology Annual Meeting & Exposition, Brown et al, December 2018

Societal Costs of Sickle Cell Disease in the United States
60th American Society of Hematology Annual Meeting & Exposition, Agodoa et al, December 2018

Development and Validation of an Oxygen Dissociation Assay, a Screening Platform for Discovering and Characterizing Hemoglobin Oxygen Affinity Modifiers
Drug Design, Development and Therapy, Patel et al, June2018

Results from a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of Voxelotor (GBT440), a HbS Polymerization Inhibitor
23rd Congress of the European Hematology Association, Brown et al, June 2018

Pharmacokinetics (PK) of Voxelotor (GBT440) Using Population Pharmacokinetic (PPK) and Physiologically Based Pharmacokinetic (PBPK) Modeling in Pediatric Subjects with Sickle Cell Disease
23rd Congress of the European Hematology Association, Washington et al, June 2018

Sickle Cell Disease Severity Measure: Development, Translation, and Patient Cultural Sensitivity Validation
23rd Congress of the European Hematology Association, Burke et al, June 2018